PALACOS^® R+G – High-Viscosity Bone Cement with Gentamicin

¹ Meinardi JE, et al. Palacos compared to Palamed bone cement in total hip replacement: a randomized controlled trial. Acta Orthop 2016; 87 (5): 473–478.
² Trela-Larsen L, et al. The association between cement type and the subsequent risk of revision surgery in primary total hip replacement. Acta Orthop 2018; 89(1): 40–46.
³ Adalberth G, et al. Fixation of the tibial component using CMW-1 or Palacos bone cement with gentamicin: similar outcome in a randomized radiostereometric study of 51 total knee arthroplasties. Acta Orthop Scand 2002; 73(5): 531–538​​​​​​​
⁴ NJR 19^th Annual Report 2022: Surgical data to 31 December 2021; 3.
⁵ NJR Implant Summary Report for Heraeus Medical GmbH. Primary Hips using PALACOS^® Antibiotic Cement: 08/2022. Page 4 and 10. Current reports accessible at http://herae.us/njr-data.
⁶ NJR Implant Summary Report for Heraeus Medical GmbH. Primary Knees using PALACOS^® Antibiotic Cement: 08/2022. Page 4 and 6. Current reports accessible at http://herae.us/njr-data.

We thank the patients and staff of all the hospitals in England, Wales, Northern Ireland and the Isle of Man who have contributed data to the National Joint Registry. We are grateful to the Healthcare Quality Improvement Partnership (HQIP), the NJR Steering Committee and staff at the NJR Centre for facilitating this work. The views expressed represent those of Heraeus Medical GmbH and do not necessarily reflect those of the National Joint Registry Steering Committee or the Health Quality Improvement Partnership (HQIP) who do not vouch for how the information is presented.